DK0497997T3 - Syntetiske membranvesikler indeholdende funktionelt aktive fusionspeptider som systemer til afgivelse af lægemidler - Google Patents

Syntetiske membranvesikler indeholdende funktionelt aktive fusionspeptider som systemer til afgivelse af lægemidler

Info

Publication number: DK0497997T3
Authority: DK; Denmark
Prior art keywords: membrane; weight; phospholipid; cell; detergent
Prior art date: 1991-02-02

Application number

DK91101414.0T

Other languages

English (en)

Inventor

Reinhard Dr Glueck

Peter Dr Herrmann

Peter Klein

Original Assignee

Nika Health Products Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-02-02

Filing date

1991-02-02

Publication date

1995-11-27

1991-02-02 Application filed by Nika Health Products Ltd filed Critical Nika Health Products Ltd

1995-11-27 Application granted granted Critical

1995-11-27 Publication of DK0497997T3 publication Critical patent/DK0497997T3/da

Links

239000012528 membrane Substances 0.000 title abstract 5
230000004927 fusion Effects 0.000 title abstract 3
108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
238000012377 drug delivery Methods 0.000 title 1
102000004196 processed proteins & peptides Human genes 0.000 title 1
239000003599 detergent Substances 0.000 abstract 3
150000003904 phospholipids Chemical class 0.000 abstract 3
101710154606 Hemagglutinin Proteins 0.000 abstract 2
101710093908 Outer capsid protein VP4 Proteins 0.000 abstract 2
101710135467 Outer capsid protein sigma-1 Proteins 0.000 abstract 2
101710176177 Protein A56 Proteins 0.000 abstract 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
239000003814 drug Substances 0.000 abstract 2
239000000185 hemagglutinin Substances 0.000 abstract 2
208000030507 AIDS Diseases 0.000 abstract 1
201000009030 Carcinoma Diseases 0.000 abstract 1
239000004971 Cross linker Substances 0.000 abstract 1
JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 abstract 1
239000004793 Polystyrene Substances 0.000 abstract 1
241000700605 Viruses Species 0.000 abstract 1
230000000840 anti-viral effect Effects 0.000 abstract 1
230000004071 biological effect Effects 0.000 abstract 1
235000012000 cholesterol Nutrition 0.000 abstract 1
229940079593 drug Drugs 0.000 abstract 1
239000003550 marker Substances 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
YYELLDKEOUKVIQ-UHFFFAOYSA-N octaethyleneglycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCO YYELLDKEOUKVIQ-UHFFFAOYSA-N 0.000 abstract 1
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 abstract 1
150000008104 phosphatidylethanolamines Chemical class 0.000 abstract 1
229920002223 polystyrene Polymers 0.000 abstract 1
-1 sulfosuccinimidyl Chemical group 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1277—Preparation processes; Proliposomes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6839—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting material from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
- A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Dispersion Chemistry (AREA)
Immunology (AREA)
Virology (AREA)
Chemical Kinetics & Catalysis (AREA)
Cell Biology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Molecular Biology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Manufacturing Of Micro-Capsules (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Feedback Control In General (AREA)
Fittings On The Vehicle Exterior For Carrying Loads, And Devices For Holding Or Mounting Articles (AREA)
Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)

DK91101414.0T 1991-02-02 1991-02-02 Syntetiske membranvesikler indeholdende funktionelt aktive fusionspeptider som systemer til afgivelse af lægemidler DK0497997T3 (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP91101414A EP0497997B1 (en)	1991-02-02	1991-02-02	Synthetic membrane vesicles containing functionally active fusion peptides as drug delivery systems

Publications (1)

Publication Number	Publication Date
DK0497997T3 true DK0497997T3 (da)	1995-11-27

Family

ID=8206362

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK91101414.0T DK0497997T3 (da)	1991-02-02	1991-02-02	Syntetiske membranvesikler indeholdende funktionelt aktive fusionspeptider som systemer til afgivelse af lægemidler

Country Status (22)

Country	Link
US (1)	US6040167A (da)
EP (1)	EP0497997B1 (da)
JP (1)	JP3404037B2 (da)
KR (1)	KR100205693B1 (da)
AT (1)	ATE125154T1 (da)
AU (1)	AU657730B2 (da)
BG (1)	BG61215B1 (da)
BR (1)	BR9204116A (da)
CA (1)	CA2079685C (da)
DE (1)	DE69111414T2 (da)
DK (1)	DK0497997T3 (da)
ES (1)	ES2077086T3 (da)
FI (1)	FI109969B (da)
GE (1)	GEP20002229B (da)
GR (1)	GR3017490T3 (da)
HK (1)	HK56696A (da)
HU (1)	HU215533B (da)
NO (1)	NO306194B1 (da)
PL (2)	PL296382A1 (da)
RO (1)	RO114736B1 (da)
RU (1)	RU2125868C1 (da)
WO (1)	WO1992013525A1 (da)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5603872A (en) *	1991-02-14	1997-02-18	Baxter International Inc.	Method of binding recognizing substances to liposomes
DK0525132T3 (da) *	1991-02-14	1996-02-05	Baxter Int	Binding af genkendende stoffer til liposomer
US7097839B1 (en) *	1993-10-26	2006-08-29	Thomas Jefferson University	ST receptor binding compounds and methods of using the same
US5879656A (en) *	1993-10-26	1999-03-09	Thomas Jefferson University	Methods of treating metastatic colorectal cancer with ST receptor binding compounds
WO1995032706A1 (en) *	1994-05-31	1995-12-07	Inex Pharmaceuticals Corp.	Virosome-mediated intracellular delivery of therapeutic agents
US6861053B1 (en) *	1999-08-11	2005-03-01	Cedars-Sinai Medical Center	Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US5908777A (en) *	1995-06-23	1999-06-01	University Of Pittsburgh	Lipidic vector for nucleic acid delivery
AU6691496A (en) *	1995-08-01	1997-02-26	Advanced Therapies, Inc.	Enhanced artificial viral envelopes for cellular delivery of therapeutic substances
CZ299809B6 (cs) *	1996-05-08	2008-12-03	Nika Health Products Limited	Lipidový vácek mající kladne nabitou membránu z lipidové dvojvrstvy pro prenos genetického materiálu a zpusob jeho prípravy
EP1141007B1 (en) *	1998-12-14	2013-05-15	Dendreon Corporation	Compositions and methods for enhancement of major histocompatibility complex class i restricted antigen presentation
US7148324B1 (en)	1998-12-14	2006-12-12	Dendreon Corporation	Compositions and methods for enhancement of major histocompatibility complex class I restricted antigen presentation
JP2004513059A (ja)	1998-12-24	2004-04-30	ユセベ，ソシエテ　アノニム	ペプチド産物、方法及び組成物
MXPA02001417A (es) *	1999-08-09	2002-08-12	Lexigen Pharm Corp	Complejos multiples de citosina-anticuerpo.
CZ20021216A3 (cs) *	1999-10-08	2002-10-16	Nika Health Products Limited	Lipidové váčky obsahující DOSPER
JP4112860B2 (ja) *	1999-12-17	2008-07-02	ショットアクチエンゲゼルシャフト	乗員の拘束システムの誘導作動式点火カプセルおよび点火カプセル用のテスト回路
US20040028687A1 (en) *	2002-01-15	2004-02-12	Waelti Ernst Rudolf	Methods and compositions for the targeted delivery of therapeutic substances to specific cells and tissues
US20040176283A1 (en) *	2002-04-01	2004-09-09	Robinson John A.	Methods and compositions for the design of synthetic vaccines
AU2003233981A1 (en) *	2002-04-29	2003-11-17	Biotesys Gmbh	Transport system in biological systems
EP1447080A1 (en) *	2003-02-13	2004-08-18	Bestewil Holding B.V.	Method for producing virosome-like particles
US8658203B2 (en)	2004-05-03	2014-02-25	Merrimack Pharmaceuticals, Inc.	Liposomes useful for drug delivery to the brain
LT3173073T (lt)	2004-05-03	2025-01-10	Ipsen Biopharm Ltd.	Liposomos, skirtos vaistų pristatymui
WO2007048019A2 (en) *	2005-10-20	2007-04-26	The Penn State Research Foundation	Delivery system for diagnostic and therapeutic agents
WO2009016433A2 (en) *	2006-09-15	2009-02-05	Ottawa Health Research Institute	Oncolytic rhabdovirus
EP4647126A3 (en)	2015-10-16	2026-02-11	Ipsen Biopharm Ltd.	Stabilizing camptothecin pharmaceutical compositions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3173713D1 (en) *	1980-09-05	1986-03-20	Frappier Armand Inst	Formation of an immunosome exclusively made of viral antigens reconstituted on an artificial membrane
US4871488A (en) *	1985-04-22	1989-10-03	Albany Medical College Of Union University	Reconstituting viral glycoproteins into large phospholipid vesicles
US4663161A (en) *	1985-04-22	1987-05-05	Mannino Raphael J	Liposome methods and compositions
US5000960A (en) *	1987-03-13	1991-03-19	Micro-Pak, Inc.	Protein coupling to lipid vesicles
IL86650A0 (en) *	1987-06-30	1988-11-30	Biophor Corp	Animal derived cells and liposomes,having an antigenic protein incorporated into their membrane
AU6358890A (en) *	1989-09-01	1991-04-08	Board Of Regents, The University Of Texas System	Immunoliposomes for transmittal of activating signals to cells
AU652778B2 (en) *	1990-10-15	1994-09-08	Quest International B.V.	Treatment composition

1991
- 1991-01-17 PL PL29638291A patent/PL296382A1/xx unknown
- 1991-02-02 AT AT91101414T patent/ATE125154T1/de not_active IP Right Cessation
- 1991-02-02 DE DE69111414T patent/DE69111414T2/de not_active Expired - Fee Related
- 1991-02-02 EP EP91101414A patent/EP0497997B1/en not_active Expired - Lifetime
- 1991-02-02 ES ES91101414T patent/ES2077086T3/es not_active Expired - Lifetime
- 1991-02-02 DK DK91101414.0T patent/DK0497997T3/da active
1992
- 1992-01-17 WO PCT/EP1992/000089 patent/WO1992013525A1/en not_active Ceased
- 1992-01-17 GE GEAP19921215A patent/GEP20002229B/en unknown
- 1992-01-17 RU SU5053247A patent/RU2125868C1/ru not_active IP Right Cessation
- 1992-01-17 AU AU11693/92A patent/AU657730B2/en not_active Ceased
- 1992-01-17 CA CA002079685A patent/CA2079685C/en not_active Expired - Fee Related
- 1992-01-17 RO RO92-01271A patent/RO114736B1/ro unknown
- 1992-01-17 US US07/930,593 patent/US6040167A/en not_active Expired - Fee Related
- 1992-01-17 JP JP50347192A patent/JP3404037B2/ja not_active Expired - Fee Related
- 1992-01-17 HU HU9203141A patent/HU215533B/hu not_active IP Right Cessation
- 1992-01-17 BR BR929204116A patent/BR9204116A/pt not_active Application Discontinuation
- 1992-01-17 PL PL92296382A patent/PL170169B1/pl not_active IP Right Cessation
- 1992-09-24 NO NO923703A patent/NO306194B1/no not_active IP Right Cessation
- 1992-09-29 BG BG96928A patent/BG61215B1/bg unknown
- 1992-10-01 KR KR1019920702402A patent/KR100205693B1/ko not_active Expired - Fee Related
- 1992-10-01 FI FI924418A patent/FI109969B/fi active
1995
- 1995-09-21 GR GR950402607T patent/GR3017490T3/el unknown
1996
- 1996-03-28 HK HK56696A patent/HK56696A/en not_active IP Right Cessation

Also Published As

Publication number	Publication date
GEP20002229B (en)	2000-09-25
JPH05505406A (ja)	1993-08-12
RO114736B1 (ro)	1999-07-30
AU657730B2 (en)	1995-03-23
KR100205693B1 (en)	1999-07-01
JP3404037B2 (ja)	2003-05-06
NO306194B1 (no)	1999-10-04
AU1169392A (en)	1992-09-07
FI109969B (fi)	2002-11-15
BG96928A (bg)	1994-03-24
EP0497997B1 (en)	1995-07-19
GR3017490T3 (en)	1995-12-31
HU215533B (hu)	1999-01-28
CA2079685C (en)	2001-11-27
FI924418A7 (fi)	1993-04-03
RU2125868C1 (ru)	1999-02-10
FI924418A0 (fi)	1992-10-01
DE69111414D1 (de)	1995-08-24
PL170169B1 (en)	1996-10-31
NO923703L (no)	1992-11-26
HK56696A (en)	1996-04-12
ATE125154T1 (de)	1995-08-15
NO923703D0 (no)	1992-09-24
PL296382A1 (en)	1993-11-02
US6040167A (en)	2000-03-21
HU9203141D0 (en)	1992-12-28
HUT66194A (en)	1994-10-28
BG61215B1 (en)	1997-03-31
BR9204116A (pt)	1993-06-08
ES2077086T3 (es)	1995-11-16
DE69111414T2 (de)	1996-02-01
CA2079685A1 (en)	1992-08-03
WO1992013525A1 (en)	1992-08-20
EP0497997A1 (en)	1992-08-12

Publication	Publication Date	Title
DK0497997T3 (da)	1995-11-27	Syntetiske membranvesikler indeholdende funktionelt aktive fusionspeptider som systemer til afgivelse af lægemidler
US5366737A (en)	1994-11-22	N-[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N,-tetrasubstituted ammonium lipids and uses therefor
US5550289A (en)	1996-08-27	N-(1,(1-1)-dialkyloxy)-and N-(1,(1-1)-dialkenyloxy alk-1-yl-N-N,N-tetrasubstituted ammonium lipids and uses therefor
US4789633A (en)	1988-12-06	Fused liposome and acid induced method for liposome fusion
Mizuguchi et al.	1996	Efficient gene transfer into mammalian cells using fusogenic liposome
US6120794A (en)	2000-09-19	Emulsion and micellar formulations for the delivery of biologically active substances to cells
AU741784B2 (en)	2001-12-06	Modulation of drug loading in multivesicular liposomes
US5834015A (en)	1998-11-10	Protein-lipid vesicles and autogenous vaccine comprising the same
PT883602E (pt)	2003-01-31	Compostos lipidicos e sua utilizacao por exemplo em lipossomas
ES2167308T3 (es)	2002-05-16	Un sistema de distribucion de fosfolipidos.
AU3511595A (en)	1996-03-29	Preparation of multivesicular liposomes for controlled release of active agents
DE69625213D1 (de)	2003-01-16	Mikroemulsionen zur verwendung als träger zur verabreichung von wirkstoffen
NZ332666A (en)	2000-05-26	Cationic virosomes having a positively charged lipid bilayer membrane with an integrated viral fusogenic peptide as genetic transfer systems for use in gene therapy
Jain et al.	1998	Brain drug delivery system bearing dopamine hydrochloride for effective management of parkinsonism
FI916120A0 (fi)	1991-12-23	Foerfarande foer framstaellning av vattenhaltiga liposomsuspensioner som innehaoller ett aktivt aemne.
Szoka Jr et al.	1988	Increased efficacy of phosphonoformate and phosphonoacetate inhibition of herpes simplex virus type 2 replication by encapsulation in liposomes
KR920002165A (ko)	1992-02-28	리포좀 생성물
Wood et al.	1980	Transmembrane orientation of lipophilin in phosphatidylcholine vesicles
Gonser et al.	1999	Vaccines and their transfection potency
Jaafari et al.	2002	Targeting of Liposomes to Human Keratinocytes Through Adhesive Peptides from Immunoglobulin Domains in the Presence of IFNM-γ
Fountain et al.	1982	Liposome carrier vehicle for triiodothryonine
WO1989005152A1 (en)	1989-06-15	Liposome-encapsulated anti-viral composition and method
Philippot et al.	0	LIPOSOMES as TOOLS in BASIC RESEARCH and
PopEscu	1985	Liposome-Collagen Gel Matrix: A Novel Sustained Drug Delivery System